After hours:
Chart Events
Performance Outlook
| Previous Close | 28.63 |
| Open | 28.65 |
| Bid | 28.76 x 2900 |
| Ask | 28.77 x 4000 |
| Day's Range | 28.59 - 28.97 |
| 52 Week Range | 28.30 - 54.93 |
| Volume | |
| Avg. Volume | 31,405,728 |
| Market Cap | 162.504B |
| Beta (5Y Monthly) | 0.56 |
| PE Ratio (TTM) | 15.73 |
| EPS (TTM) | 1.83 |
| Earnings Date | Jan 29, 2024 - Feb 02, 2024 |
| Forward Dividend & Yield | 1.64 (5.70%) |
| Ex-Dividend Date | Nov 09, 2023 |
| 1y Target Est | 40.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PFE
Related Research
- Pfizer, Inc.Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.RatingFair ValueEconomic Moat9 days agoMorningstar
Business WireMarstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
NEW YORK, December 10, 2023--Pfizer Inc. (NYSE: PFE) today presented results from the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab for the treatment of people with severe hemophilia A and moderately severe to severe hemophilia B without inhibitors to Factor VIII (FVIII) or Factor IX (FIX). The results from the BASIS trial demonstrated a statistically significant and clinically meaningful effect on annualized bleeding rate (ABR). The findings were presented today at t
BioPharma DiveASH23: CAR-T for autoimmune disease, real-world questions and sickle cell’s social media mentions
Study results disclosed at the American Society of Hematology meeting Saturday suggested potential for cell therapy in lupus and pointed out drug trial limitations.
Motley Fool3 Dividend Stocks Trading at 52-Week Lows
I have always stated that stocks should not be bought just because they trade at a 52-week low. A new 52-week low does not make a particular stock cheap. In today's video I will look at three dividend stocks trading at their 52-week lows and examine their metrics to determine if the stock is cheap or not.
